Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485231 | 0.92 | MAPT (0.48) | EGLN1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20827027 | 0.92 | SMN1; SMN2 (0.54) | MAPTSMN1; SMN2RAB9ANPC1GAA | |
| SCHEMBL23207493 | 0.91 | EPHX2 (0.41) | EGLN1SMYD3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL11412912 | 0.90 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2RAB9ANPC1GAA | |
| SCHEMBL9865762 | 0.90 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2RAB9ANPC1GAA | |
| SCHEMBL6989749 | 0.87 | EPHX1 (0.50) | EGLN1SMYD3MAPTRAB9ANPC1 | |
| SCHEMBL24754980 | 0.84 | EPHX2 (0.44) | EGLN1SMYD3MAPTRAB9ANPC1 | |
| SCHEMBL10652333 | 0.82 | SMYD3 (0.44) | EGLN1SMYD3MAPTRAB9ANPC1 | |
| SCHEMBL18459805 | 0.80 | ALDH1A1 (0.48) | EGLN1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7788916 | 0.78 | SMYD3 (0.47) | SMYD3SMN1; SMN2GAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776522-B | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3710006-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Northern Industrial Area, (CN) | 2019-05-23 | — | — | US | disclosed |
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2958915-B1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150051203-A1 | TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2015-02-19 | — | — | US | disclosed |
| WO-2014128585-A1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2013148857-A1 | TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051203-A1 | TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | EGLN1 942/4885SMYD3 4136/4885MAPT 233/4885 |
| US-20150322065-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | EGLN1 3161/4885SMYD3 860/4885MAPT 4007/4885 |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | EGLN1 3664/4885SMYD3 3190/4885MAPT 2017/4885 |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | PRKACA, PRKDC, PRKACB | EGLN1 3664/4885SMYD3 3190/4885MAPT 2017/4885 |
| US-20140235612-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | EGLN1 3161/4885SMYD3 860/4885MAPT 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.